Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Other solid neoplasm 1Gynecologic 1Genitourinary 1Dermatologic 1

Conditions

Sarcoma 316Glioblastoma 176Gliosarcoma 166Astrocytoma 125Brain Neoplasms 117Osteosarcoma 101Glioma 97Central Nervous System Neoplasms 96Oligodendroglioma 92Neuroblastoma 88Neoplasms 87Melanoma 87Breast Neoplasms 81Ovarian Neoplasms 70Lymphoma 67Dendritic Cell Sarcoma, Interdigitating 64Sarcoma, Ewing 63Rhabdomyosarcoma 63Recurrence 63Carcinoma, Non-Small-Cell Lung 62Precursor Cell Lymphoblastic Leukemia-Lymphoma 59Burkitt Lymphoma 59Lymphoma, Non-Hodgkin 55Medulloblastoma 53Wilms Tumor 52Colorectal Neoplasms 52Pancreatic Neoplasms 51Neoplasm Metastasis 49Lymphoma, Large B-Cell, Diffuse 47Carcinoma, Hepatocellular 44

Interventions

Taxes 1Immunoglobulin G 1Disulfides 1Bevacizumab 1Albumin-Bound Paclitaxel 1130-nm albumin-bound paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Cervical Adenocarcinoma × Sarcoma × Clear all
NCT02020707 2024-07-26

Nab-Paclitaxel and Bevacizumab in Treating Patients With Unresectable Stage IV Melanoma or Gynecological Cancers

Mayo Clinic

Phase 1 Completed
43 enrolled
DermatologicGenitourinaryGynecologicOther solid neoplasmSarcoma

Cervical Adenocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡